Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Inclusion Criteria: * Male or female aged \>= 6 months to =\<35 months at the time of the first study vaccination. Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg * Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative Subject and parent/legal representative are able to attend all scheduled visits and to comply with all trial procedures Exclusion Criteria: * Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination * Planned participation in another clinical trial during the present trial period * Receipt of any vaccine in the 4 weeks preceding the first trial vaccination * Planned receipt of any vaccine prior to the Day 42 blood sample * Receipt of blood or blood-derived products in the past 3 months which might interfere with the assessment of immune response * Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances * Thrombocytopenia contraindicating intramuscular (IM) vaccination as reported by parents/legal representative * Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination * Chronic illness that in the opinion of the Investigator is at a stage where it might interfere with trial conduct or completion * Family members of the employees or the Investigator * Previous participation in a trial investigating a vaccine with the swine-origin A/H1N1 influenza strain * Confirmed infection with the novel influenza A/H1N1 strain * Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment